[PDF] Epidemiological profil on adverse effects of

How many adverse reactions are there?

Among the 16 included studies, 10 studies reported the incidence of total adverse reactions, 10 reported the incidence of systemic and local adverse reactions, and 15 studies reported the incidence of single adverse reactions including pain, swelling, erythema, fatigue, headache and fever. 3.1. Total adverse events

Are individualized biomarkers needed to assess Irae risk?

Clinically validated biomarkers enabling individualized assessments of the risk of irAEs are still lacking. IrAEs can occur early in the course of treatment and are sometimes associated with a severe clinical presentation. Such variations in severity suggest the presence of pre-existing factors influencing their occurrence (Box 2 ).

Is anti-PD-1 induced pneumonitis more common in patients with melanoma?

The demographics of patients with pneumonitis have provided important insights into the pathogenesis of this irAE. Anti-PD-1 or anti-PD-L1 antibody-induced pneumonitis is more frequent in the first-line setting and has both a greater incidence and severity in patients with NSCLC than in those with melanoma 28, 63.